988 related articles for article (PubMed ID: 34473525)
1. Recent Advances in the Management of Metastatic Prostate Cancer.
Sayegh N; Swami U; Agarwal N
JCO Oncol Pract; 2022 Jan; 18(1):45-55. PubMed ID: 34473525
[TBL] [Abstract][Full Text] [Related]
2. Recent Development and Future Prospects of Molecular Targeted Therapy in Prostate Cancer.
Zhang J; Sun J; Bakht S; Hassan W
Curr Mol Pharmacol; 2022; 15(1):159-169. PubMed ID: 34102978
[TBL] [Abstract][Full Text] [Related]
3. Current management of metastatic castration-sensitive prostate cancer.
Kessel A; Kohli M; Swami U
Cancer Treat Res Commun; 2021; 28():100384. PubMed ID: 33951556
[TBL] [Abstract][Full Text] [Related]
4. A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer.
De La Cerda J; Dunshee C; Gervasi L; Sieber P; Belkoff L; Tutrone R; Lu S; Gatoulis SC; Brown B; Migoya E; Shore N
Target Oncol; 2023 May; 18(3):383-390. PubMed ID: 37060432
[TBL] [Abstract][Full Text] [Related]
5. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
6. Advances in the treatment of metastatic prostate cancer.
Gebrael G; Fortuna GG; Sayegh N; Swami U; Agarwal N
Trends Cancer; 2023 Oct; 9(10):840-854. PubMed ID: 37442702
[TBL] [Abstract][Full Text] [Related]
7. PARP inhibitors in prostate cancer: practical guidance for busy clinicians.
VanderWeele DJ; Hussain M
Clin Adv Hematol Oncol; 2020 Dec; 18(12):808-815. PubMed ID: 33406057
[TBL] [Abstract][Full Text] [Related]
8. Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer.
Adashek JJ; Jain RK; Zhang J
Cells; 2019 Aug; 8(8):. PubMed ID: 31404966
[TBL] [Abstract][Full Text] [Related]
9. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
10. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
Damodaran S; Lang JM; Jarrard DF
J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
[TBL] [Abstract][Full Text] [Related]
11. Olaparib for Metastatic Castration-Resistant Prostate Cancer.
de Bono J; Mateo J; Fizazi K; Saad F; Shore N; Sandhu S; Chi KN; Sartor O; Agarwal N; Olmos D; Thiery-Vuillemin A; Twardowski P; Mehra N; Goessl C; Kang J; Burgents J; Wu W; Kohlmann A; Adelman CA; Hussain M
N Engl J Med; 2020 May; 382(22):2091-2102. PubMed ID: 32343890
[TBL] [Abstract][Full Text] [Related]
12. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
13. [New treatment approaches for and ongoing trials in metastatic hormone-sensitive prostate cancer].
Isgandarov A; Darr C; Posdzich P; Hermann K; Hadaschik BA; Grünwald V
Urologie; 2023 Apr; 62(4):369-375. PubMed ID: 36823372
[TBL] [Abstract][Full Text] [Related]
14. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
[TBL] [Abstract][Full Text] [Related]
15. Research progress on the treatment of advanced prostate cancer with Olaparib.
Su YX; Yu CF; Xue P; Li LL; Xiao KM; Chu XL; Zhu SJ
Neoplasma; 2021 Nov; 68(6):1132-1138. PubMed ID: 34779643
[TBL] [Abstract][Full Text] [Related]
16. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer Harboring Somatic or Germline Homologous Recombination Repair Gene Mutations: Phase II Single-Arm Trial.
Jain R; Kumar A; Sharma A; Sahoo RK; Sharma A; Seth A; Nayak B; Shamim SA; Kaushal S; Kp H; Das CJ; Batra A
JMIR Res Protoc; 2024 Apr; 13():e54086. PubMed ID: 38453159
[TBL] [Abstract][Full Text] [Related]
18. Olaparib for the treatment of metastatic prostate cancer.
Dror CM; Wyatt AW; Chi KN
Future Oncol; 2021 Jul; 17(19):2413-2429. PubMed ID: 33769071
[TBL] [Abstract][Full Text] [Related]
19. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
20. Relugolix in the management of prostate cancer.
Sahu KK; Tripathi N; Agarwal N; Swami U
Expert Rev Anticancer Ther; 2022 Sep; 22(9):891-902. PubMed ID: 35866612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
